AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease.

NCT02826525 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

T2DM With NAFLD

Interventions

DRUG: AZD4076
DRUG: Placebo

Sponsor

AstraZeneca